Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019544 | 0.92 | MAOA (1.00) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL13298923 | 0.87 | MAOA (0.82) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5656310 | 0.83 | MAOA (1.00) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL4015548 | 0.82 | MAOA (0.73) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5658198 | 0.82 | MAOA (0.86) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL13939808 | 0.82 | MAOA (0.80) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL4020689 | 0.82 | MAOA (0.85) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5670931 | 0.82 | MAOA (0.88) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5659989 | 0.82 | MAOA (1.00) | MAOACYP3A4CYP2D6KCNH2 | |
| SCHEMBL5656637 | 0.82 | MAOA (0.85) | MAOACYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | claimed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | claimed |
| EP-1497286-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003072575-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | claimed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | MAOA 1576/4885CYP3A4 38/4885CYP2D6 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.